Ye Wenqing, Voss Maurice D, Athreya Sriharsha
Michael G. DeGroote School of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
Centre for Interventional Radiology and Oncology (CIRO), St. Joseph's Healthcare, Hamilton, ON, Canada.
Cardiovasc Intervent Radiol. 2018 Jun;41(6):828-834. doi: 10.1007/s00270-018-1890-7. Epub 2018 Jan 31.
Symptomatically enlarged kidneys observed in autosomal dominant polycystic kidney disease (ADPKD) patients can lead to compression symptoms and contraindications to renal transplantation. Surgical nephrectomy can be utilized to increase space in the abdomen prior to renal transplantation; however, not all individuals are appropriate candidates for this procedure. Transcatheter arterial embolization (TAE) of the renal arteries can provide a noninvasive way to reduce renal volume in ADPKD.
We performed a systematic literature review on the usage of TAE to reduce renal volume prior to kidney transplantation and to relief compression symptoms in ADPKD. PubMed, Web of Science, and Cochrane Library were searched for articles focused on the usage of TAE to reduce renal volume in symptomatic enlarged kidneys. Renal volume data were compiled, and meta-analysis was performed with three or more studies.
Six papers satisfied the inclusion and exclusion criteria. Significant renal volume reduction was observed by 12 months in all studies. Success of TAE was measured with three clinical outcomes: removal of contraindication for renal transplant, relief of compression symptoms, and pulmonary function test. Proportionality meta-analysis of three studies measuring relief of compression symptoms showed no significant differences in heterogeneity (p = 0.4543).
Current studies conclude that TAE is an effective and minimally invasive option for reduction in renal volume in order to optimize patient outcome for renal transplantation and for relief of compression symptoms. Further prospective studies involving increased sample size and multiple centers should be pursued to establish evidence-based guidelines.
常染色体显性多囊肾病(ADPKD)患者出现的症状性肾脏增大可导致压迫症状及肾移植禁忌。手术肾切除术可用于在肾移植前增加腹腔空间;然而,并非所有个体都适合该手术。肾动脉经导管动脉栓塞术(TAE)可为减少ADPKD患者的肾脏体积提供一种非侵入性方法。
我们对TAE在肾移植前减少肾脏体积及缓解ADPKD压迫症状方面的应用进行了系统的文献综述。检索了PubMed、科学网和Cochrane图书馆,查找聚焦于TAE用于减少有症状增大肾脏体积的文章。汇总肾脏体积数据,并对三项或更多研究进行荟萃分析。
六篇论文符合纳入和排除标准。所有研究均观察到12个月时肾脏体积显著减小。TAE的成功通过三项临床结果衡量:消除肾移植禁忌、缓解压迫症状和肺功能测试。对三项衡量压迫症状缓解情况的研究进行的比例荟萃分析显示异质性无显著差异(p = 0.4543)。
当前研究得出结论,TAE是减少肾脏体积的一种有效且微创的选择,可优化肾移植患者的预后并缓解压迫症状。应开展进一步的前瞻性研究,纳入更多样本量并涉及多个中心,以制定循证指南。